Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2000-01-20
2002-08-13
Stucker, Jeffrey (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S350000, C424S085400, C435S007100
Reexamination Certificate
active
06433145
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a novel human gene encoding a polypeptide which is a member of the interferon family. More specifically, isolated nucleic acid molecules are provided encoding a human polypeptide named “Keratinocyte Derived Interferon” or “KDI”. KDI polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system, and therapeutic methods for treating disorders of the immune system. The invention further relates to screening methods for identifying agonists and antagonists of KDI.
BACKGROUND OF THE INVENTION
Human interferons (IFNs) are a well known family of cytokines secreted by a large variety of eukaryotic cells upon exposure to various stimuli. The interferons have been classified by their chemical and biological characteristics into five groups: IFN-alpha (leukocytes), IFN-beta (fibroblasts), IFN-gamma (lymphocytes), IFN-omega (leukocytes) and IFN-tau (trophoblasts). IFN-alpha, IFN-beta, IFN-omega and IFN-tau are known as Type I interferons; IFN-gamma is known as a Type-H or immune interferon. A single functional gene in the human genome codes for interferon omega (IFN-omega), a monomeric glycoprotein distantly related in structure to IFN-alpha and IFN-beta, but unrelated to IFN-gamma. IFN-omega is secreted by virus-infected leukocytes as a major component of human leukocyte interferon. The IFNs exhibit anti-viral, immunoregulatory, and antiproliferative activity. The clinical potential of interferons has been recognized, and will be summarized below.
The Interferons (IFNs) were initially identified by their anti-viral activity and are divided into two classes: type 1 and type II. The type I IFNs are further subdivided into three sub-groups. IFN alpha, a group of 14 individual genes with 13 functional and one pseudogene; their major site of synthesis is in leukocytes and they are 165-166 amino acids in length. IFN Beta, a group of 1 functional gene and no pseudogenes; its major site of synthesis is in viral induced fibroblasts and epithelial cells and it is 166 amino acids in length. IFN omega, a group of 7 individual genes with 1 functional and 6 pseudogenes; the functional gene is expressed upon viral induction in leukocytes. The third sub-group within the type I interferons is trophoblast interferon, IFN tau, which was originally discovered in ruminant trophoblasts and later in humans as well. Whaley et al., J. Biol. Chem. 269: 10864-8 (1994).
The structural genes for all type I IFNs are located within a 400,000 base pair region on the short arm of chromosome 9 (human). None of the genes contain an intron and the proteins encoded by the functional genes all appear to share a common receptor, the type I IFN-R composed of IFNAR1 and IFNAR2 subunits. IFNAR2 has a short, long and soluble form). While they bind the same receptor there appears to be subsequent signaling differences. In contrast to the type I IFNs there is only one member of the type II IFN, namely IFN gamma, which is encoded by a single gene (containing three introns) located on chromosome 12. The protein is produced predominantly by T lymphocytes and NK cells, is 166 amino acids in length and shows no homology to type I interferons.
A range of biological activities are associated with IFNs including antiviral, anti-proliferative and immunoregulatory activities. IFN alpha is marketed by Schering Plough (Intron; IFN alpha 2B) and Hoffman La Roche (Roferon; IFN alpha 2A). Therapeutic uses include the treatment of Hairy Cell leukemia, Chronic myelogenous leukemia, low grade non-Hodgkin lymphoma, cutaneous T cell lymphoma carcinoid tumors, renal cell carcinoma, squamous epithelial tumors of the head and neck, multiple myeloma, and malignant melanoma. With regards to viral disease, Interferon alpha has been found to aid the treatment of chronic active hepatitis, caused by either Hepatitis B or C viruses. IFN Beta has been demonstrated to have clinical benefit in the treatment of multiple sclerosis. Clinical trials with Interferon gamma have shown potential in the treatment of cutaneous and also visceral leishmanias.
Anti-viral
IFNs have been used clinically for anti-viral therapy, for example, in the treatment of AIDS (HIV infection) (Lane,
Semin. Oncol.
18:46-52 (October, 1991)), viral hepatitis including chronic hepatitis B, hepatitis C (Woo, M. H. and Brunakis, T. G.,
Ann. Parmacother,
31:330-337 (March 1997); Gibas, A. L.,
Gastroenterologist,
1:129-142 (June 1993)), hepatitis D, papilloma viruses (Levine, L. A. et al.,
Urology
47:553-557 (April 1996)), herpes (Ho, M.,
Ann. Rev. Med.
38:51-59 (1987)), viral encephalitis (Wintergerst et al.,
Infection,
20:207-212 (July 1992)), respiratory syncytial virus, panencephalitis, mycosis fungoides and in the prophylaxis of rhinitis and respiratory infections (Ho, M.,
Annu. Rev. Med.
38:51-59 (1987)).
Anti-parasitic
IFNs have been suggested for anti-parasite therapy, for example, IFN-gamma for treating
Cryptosporidium parvum
infection (Rehg, J. E.,
J. Infect. Des.
5 174:229-232 (July 1996)).
Anti-bacterial
IFNs have been used clinically for anti-bacterial therapy. For example, IFN-gamma has been used in the treatment of multidrug-resistant pulmonary tuberculosis (Condos, R. et al.,
Lancet
349:1513-1515 (1997)).
Anti-cancer
Interferon therapy has been used in the treatment of numerous cancers (e.g., hairy cell leukemia (Hoffmann et al.,
Cancer Treat. Rev.
12 (Suppl. B):33-37 (December 1985)), acute myeloid leukemia (Stone, R. M. et al.
Am. J. Clin. Oncol.
16:159-163 (April 1993)), osteosarcoma (Strander, H. et al.,
Acta Oncol.
34:877-880 (1995)), basal cell carcinoma (Dogan, B. et al.,
Cancer Lett.
91:215-219 (May 1995)), glioma (Fetell, M. R. et al.,
Cancer
65: 78-83 (January, 1990)), renal cell carcinoma (Aso, Y. et al.
Prog. Clin. Biol. Res.
303:653-659 (1989)), multiple myeloma (Peest, D. et al.,
Br. J. Haematol.
94:425-432 (September, 1996)), melanoma (Ikic, D. et al.,
Int. J. Dermatol.
34:872-874 (December, 1995)), myelogenous leukemia, colorectal cancer, cutaneous T cell lymphoma, myelodysplastic syndrome, glioma, head and neck cancer, breast cancer, gastric cancer, anti-cancer vaccine therapy, and Hodgkin's disease (Rybak, M. E. et al.,
J. Biol. Response Mod.
9:1-4 (February, 1990)). Synergistic treatment of advanced cancer with a combination of alpha interferon and temozolomide has also been reported (Patent publication WO 9712630 to Dugan, M. H.).
Immunotherapy
IFNs have been used clinically for immunotherapy or more particularly, (1) for example, to prevent graft vs. host rejection, or to curtail the progression of autoimmune diseases, such as arthritis, multiple sclerosis, (2) or diabetes (3). IFN-beta is approved of sale in the United States for the treatment (i.e., as an immunosuppressant) of multiple sclerosis. Recently it has been reported that patients with multiple sclerosis have diminished production of type I interferons and interleukin-2 (Wandinger, K. P. et al.,
J. Neurol. Sci.
149: 87-93 (1997)). In addition, immunotherapy with recombinant IFN-alpha (in combination with recombinant human L-2) has been used successfully in lymphoma patients following autologous bone marrow or blood stem cell transplantation, that may intensify remission following translation (Nagler, A. et al.,
Blood
89: 3951-3959 (June, 1997)).
Anti-allergy
The administration of IFN-gamma has been used in the treatment of allergies in mammals (See, Patent Publication WO 8701288 to Parkin, J. M. and Pinching, A. J.). It has also recently been demonstrated that there is a reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma (van der Pouw Kraan, T. C. et al.,
J. Immunol.
158:5560-5565 (1997)). Thus, IFN may be useful in the treatment of allergy by inhibiting the humoral response.
Vaccine Adjuvantation
Interferons may be used as an adjuvant or coadjuvant to enhance or simulate the immune response in cases of prophylactic or
LaFleur David W.
Moore Paul A.
Ruben Steven M.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Seharaseyon Jegatheesan
Stucker Jeffrey
LandOfFree
Keratinocyte derived interferon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Keratinocyte derived interferon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Keratinocyte derived interferon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2904776